DreaMed Diabetes
The latest approval marks DreaMed’s fourth clearance from the Food and Drug Administration.
Also IntelyCare makes slew of new hires and PixCell Medical adds to board chair.
Interest in digital health is now sprouting up all over DC, from the president’s announcement of a new AI task force to FDA Commissioner’s shout out to digital health in his budget request.
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.
Insulin dose tool gains CE Mark.